Cargando…
Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742822/ https://www.ncbi.nlm.nih.gov/pubmed/29261171 http://dx.doi.org/10.3390/cancers9120174 |
_version_ | 1783288460387287040 |
---|---|
author | Musumeci, Domenica Platella, Chiara Riccardi, Claudia Moccia, Federica Montesarchio, Daniela |
author_facet | Musumeci, Domenica Platella, Chiara Riccardi, Claudia Moccia, Federica Montesarchio, Daniela |
author_sort | Musumeci, Domenica |
collection | PubMed |
description | Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary structure switches induced by target recognition are suitably translated in a detectable fluorescent signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-invasive in vivo imaging tools for cancer pre- and post-treatment assessment. |
format | Online Article Text |
id | pubmed-5742822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57428222017-12-29 Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics Musumeci, Domenica Platella, Chiara Riccardi, Claudia Moccia, Federica Montesarchio, Daniela Cancers (Basel) Review Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary structure switches induced by target recognition are suitably translated in a detectable fluorescent signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-invasive in vivo imaging tools for cancer pre- and post-treatment assessment. MDPI 2017-12-20 /pmc/articles/PMC5742822/ /pubmed/29261171 http://dx.doi.org/10.3390/cancers9120174 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Musumeci, Domenica Platella, Chiara Riccardi, Claudia Moccia, Federica Montesarchio, Daniela Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title_full | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title_fullStr | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title_full_unstemmed | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title_short | Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics |
title_sort | fluorescence sensing using dna aptamers in cancer research and clinical diagnostics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742822/ https://www.ncbi.nlm.nih.gov/pubmed/29261171 http://dx.doi.org/10.3390/cancers9120174 |
work_keys_str_mv | AT musumecidomenica fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics AT platellachiara fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics AT riccardiclaudia fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics AT mocciafederica fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics AT montesarchiodaniela fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics |